Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Exhibit 99.1
Chairman’s Address 2026 Annual General Meeting
Good morning, ladies and gentlemen, and welcome to Alterity Therapeutics' 2026 Annual General Meeting. For those I haven't had the opportunity to meet, my name is Julian Babarczy, and I am the Chairman of Alterity.
This is my first AGM as Chairman, having joined the Board of Directors following last year's AGM. It has been a particularly important and productive period for the Company, and I would like to take a few minutes to reflect on the progress we have made, and importantly, what that means for our future.
When I joined the Board, Alterity had delivered exceptional Phase 2 clinical results for ATH434 in Multiple System Atrophy, or MSA. However, a number of important questions remained around the regulatory pathway, the design of a pivotal Phase 3 trial, and the preparations required to take the program forward.
Over the past twelve months, we have made substantial progress in addressing those questions. Most significantly, following a series of constructive interactions with the US Food and Drug Administration (FDA), we now have alignment on the key elements of the design and potential registrational pathway for a Phase 3 trial of ATH434 in MSA.
This is a significant achievement for Alterity. It provides a clear framework for the next phase of development and allows us to move forward with considerably greater clarity around what is required. David will provide more detail on the FDA feedback and our Phase 3 trial design in his presentation shortly.
While there is still important work ahead, we believe the progress made over the past year has significantly strengthened our development program and provides a solid foundation as we move towards Phase 3.
In many respects, the past twelve months have represented an important transition for Alterity. We have moved from establishing encouraging clinical evidence to having a defined pathway towards a potential FDA registrational program. I believe this represents an important step forward in the maturity of the Company and the opportunity we are pursuing.
Alongside the regulatory progress, we have continued to build our scientific evidence base. Further analyses of our Phase 2 results, together with publications and presentations at major international scientific conferences, have strengthened our understanding of ATH434 and helped inform the design of the pivotal trial.
We have also made important progress in manufacturing, including the successful production of our first registration batch of ATH434, and strengthened our intellectual property position with a new US composition of matter patent extending protection to 2045.
Taken together, these developments are important not only from a clinical and regulatory perspective, but also commercially. They strengthen the potential value of ATH434 and our ability to pursue the best development and strategic opportunities for the asset.
I also want to acknowledge the significant unmet medical need we are seeking to address. MSA is a devastating, rapidly progressive neurological disease, with no approved treatment currently available to slow its progression. The potential to make a meaningful difference to patients and their families remains central to everything we do.
The past year has also seen some changes to the composition of our Board, reflecting the evolution of Alterity and the opportunities ahead.
We welcomed Ann Cunningham to the Board in April, bringing extensive global pharmaceutical and commercial experience, particularly in neurology. Together with the changes to the Board over the past year, we believe we now have a strong and complementary mix of scientific, pharmaceutical, commercial, financial and governance expertise.
As we move towards Phase 3, the decisions facing Alterity will increasingly involve significant capital commitments, potential strategic partnerships and the execution of a global clinical program. We believe the Board and management team are well positioned to execute, and to provide the oversight, strategic direction and commercial judgement required during this next stage.
I would also like to acknowledge and thank those directors who have stepped down from the Board over the past year for their contribution and service to Alterity.
As we look ahead, we are sharpening our focus on the next important phase of Alterity's development: securing the funding required to advance and successfully execute our Phase 3 program.
We finished September with A$41.3 million in cash, providing an important financial foundation as we advance our preparations. However, Phase 3 will require a substantial financial commitment, and securing the appropriate funding and development structure remains a key priority for the Board. We continue to evaluate a range of alternatives, including potential pharmaceutical partnerships and other strategic and capital funding options.
Our responsibility as a Board is to carefully assess these opportunities, balancing the need to advance ATH434 efficiently with the importance of preserving its substantial potential value and maximising long-term returns for our shareholders.
Looking forward, we have a clear objective: to secure the resources required to commence our pivotal Phase 3 trial and position the Company to execute it successfully. Operational preparations are already underway, and David will provide more detail on these activities shortly.
I am encouraged by what the team has achieved over the past year and have great confidence in the quality of our people and the program we are advancing.
On behalf of the Board, I would like to thank David and the entire Alterity team for their dedication and commitment, together with our clinical investigators and collaborators around the world.
Most importantly, I want to acknowledge the patients and their families who continue to support our research. Their contribution is fundamental to the progress we are making, and a constant reminder of why this work matters.
And finally, to our shareholders, thank you for your continued support.
Alterity enters this next stage of its development in a materially stronger position than twelve months ago. We have a defined regulatory pathway, an increasingly robust body of clinical evidence, strengthened intellectual property and a clear understanding of the next steps required to advance ATH434.
There is considerable work ahead, but I believe we have an exciting opportunity before us. The Board and management remain focused on translating the progress made to date into meaningful outcomes for patients and long-term value for our shareholders. Thank you, and I will now hand over to David for his presentation.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson’s disease and related disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease without an approved treatment. ATH434, the Company’s lead asset, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520